General Principle: Receptor Downregulation as the Mechanistic Basis for Cycling Requirements
The speaker articulates a general pharmacological principle: any compound that works by repeatedly binding and activating a specific receptor will eventually trigger receptor downregulation, where the body removes receptors from the cell surface to protect itself. This loss of receptor availability reduces the compound's effectiveness and is the core reason cycling is required for such agents. This principle is applied to distinguish BPC-157 from other peptides.
Ipamorelin and GHRP-2 Require Cycling Due to Ghrelin Receptor Downregulation
Ipamorelin and GHRP-2 are cited as examples of peptides that require cycling because they work by repeatedly stimulating the ghrelin receptor on the pituitary gland. Continuous stimulation causes the body to internalize or remove the receptor from the cell surface as a protective response, reducing efficacy over time. This receptor downregulation mechanism is used as a contrast to BPC-157's mode of action.
Receptor Downregulation Mechanism: Why Cycling Is Required for Ghrelin Receptor Agonists (Ipamorelin, GHRP-2)
Ipamorelin and GHRP-2 are cited as examples of peptides that require cycling because they repeatedly stimulate the ghrelin receptor on the pituitary gland. Continuous stimulation causes the body to internalize (downregulate) the receptor from the cell surface as a protective mechanism, reducing efficacy over time. This receptor-level downregulation is the core mechanistic reason cycling is necessary for these compounds.